Epigenetic Therapy for Breast Cancer
Author Information
Author(s): Cai Feng-Feng, Kohler Corina, Zhang Bei, Wang Ming-Hong, Chen Wei-Jie, Zhong Xiao-Yan
Primary Institution: University of Basel
Hypothesis
Epigenetic modifications should be preferred in therapy applications for breast cancer due to their reversibility.
Conclusion
Epigenetic therapy has significant potential in treating breast cancer by reversing DNA methylation and histone acetylation patterns.
Supporting Evidence
- Epigenetic changes are reversible, making them a safer alternative in breast cancer therapy.
- DNA methylation inhibitors can reactivate silenced genes in cancer cells.
- Histone deacetylation inhibitors can change cellular processes that are defective in cancerous cells.
- Combining DNMT and HDAC inhibitors has shown a synergistic effect in cancer treatment.
Takeaway
This study talks about using special drugs that can change how genes work in breast cancer, which might help treat the disease better.
Methodology
The review evaluates the potential of DNA methylation inhibitors and histone deacetylation inhibitors in breast cancer therapy.
Limitations
There has been little success in treating breast cancer with epigenetic drugs, and they are still undergoing clinical trials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website